Abstract
Von Willebrand Factor (vWF) is a large glycoprotein with a broad range of physiological and pathological functions in health and disease. While vWF is critical for normal hemostasis, vascular integrity and repair, quantitative and qualitative abnormalities in the molecule can predispose to serious bleeding and thrombosis. The heritable form of von Willebrand Disease was first described nearly a century ago, but more recently, recognition of an acquired condition known as acquired von Willebrand Syndrome (AVWF) has emerged in persons with hematological, endocrine and cardiovascular diseases, disorders and conditions. An in-depth understanding of the causes, diagnostic approach and management of AVWS is important for practicing clinicians.
Similar content being viewed by others
References
Lassila R, Lindberg O (2013) Erik von Willebrand. Haemophilia 19(5):643–647
Ruggeri ZM (2000) Role of von Willebrand factor in platelet thrombus formation. Ann Med 32(Suppl 1):2–9
Huisman B et al (2017) Modeling the cleavage of von Willebrand factor by ADAMTS13 protease in shear flow. Med Eng Phys 48:14–22
Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 67:395–424
Valentijn KM et al (2011) Functional architecture of Weibel–Palade bodies. Blood 117(19):5033–5043
Favaloro EJ, Pasalic L, Curnow J (2016) Type 2 M and Type 2A von Willebrand disease: similar but Different. Semin Thromb Hemost 42(5):483–497
Xu ER, Blythe EE (2017) Structural analyses of von Willebrand factor C domains of collagen 2A and CCN3 reveal an alternative mode of binding to bone morphogenetic protein-2. J Biol Chem 292(30):12516–12527
Casa LDC, Ku DN (2017) Thrombus formation at high shear rates. Annu Rev Biomed Eng 19:415–433
Lynch CJ, Lane DA, Luken BM (2014) Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood 123(16):2585–2592
Zhang X et al (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324(5932):1330–1334
Bharati KP, Prashanth UR (2011) Von Willebrand disease: an overview. Indian J Pharm Sci 73(1):7–16
Dayananda KM et al (2010) von Willebrand factor self-association on platelet GpIbalpha under hydrodynamic shear: effect on shear-induced platelet activation. Blood 116(19):3990–3998
Rack K, Huck V (2017) Margination and stretching of von Willebrand factor in the blood stream enable adhesion. 7(1):14278
Coenen DM, Mastenbroek TG (2017) Cosemans, J, Platelet interaction with activated endothelium: mechanistic insights from microfluidics. Blood. 130(26):2819–2828
Meyer D et al (2001) Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best Pract Res Clin Haematol 14(2):349–364
Sutherland JJ et al (2004) Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model 10(4):259–270
Dong JF et al (2003) ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 278(32):29633–29639
Brown SA et al (2003) Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 1(8):1714–1717
Sztukowska M et al (2008) Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 143(1):107–114
Gallinaro L et al (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540–3545
Gill JC et al (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69(6):1691–1695
van Schooten CJ et al (2008) Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112(5):1704–1712
Casari C et al (2013) Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122(16):2893–2902
Grewal PK et al (2008) The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 14(6):648–655
Pegon JN et al (2012) Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 97(12):1855–1863
Christodoulides N et al (2001) Glycoprotein Ib/IX/V binding to the membrane skeleton maintains shear-induced platelet aggregation. Thromb Res 102(2):133–142
Jy W et al (2005) Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 3(6):1301–1308
Yuan, Y., et al., Calpain regulation of cytoskeletal signaling complexes in von Willebrand factor-stimulated platelets. Distinct roles for glycoprotein Ib-V-IX and glycoprotein IIb-IIIa (integrin alphaIIbbeta3) in von Willebrand factor-induced signal transduction. J Biol Chem, 1997. 272(35): p. 21847-54
Randi AM, Smith KE, Castaman G (2018) von Willebrand factor regulation of blood vessel formation. Blood 132(2):132–140
Zimmerman TS, Ratnoff OD, Powell AE (1971) Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 50(1):244–254
Boender, J., et al., Clinically relevant differences between assays for von Willebrand factor activity. J Thromb Haemost, 2018
Just S (2017) Laboratory Testing for von Willebrand Disease: the Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin. Semin Thromb Hemost 43(1):75–91
Nichols WL et al (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14(2):171–232
Chapin J (2018) Von Willebrand disease in the elderly: clinical perspectives. Clin Interv Aging 13:1531–1541
Favaloro EJ et al (2018) Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study. Thromb Res 166:96–105
Tiede A et al (2011) How I treat the acquired von Willebrand syndrome. Blood 117(25):6777–6785
Deconinck S et al (2018) Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome. Res Pract Thromb Haemost 2(4):762–766
Waldow HC et al (2014) Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol 176(3):739–745
Binnetoglu FK et al (2016) Acquired von Willebrand syndrome in children with aortic and pulmonary stenosis. Cardiovasc J Afr 27(4):222–227
Massyn, M.W. and S.A. Khan, Heyde syndrome: a common diagnosis in older patients with severe aortic stenosis. Age Ageing, 2009. 38(3): p. 267-70; discussion 251
Warkentin TE, Moore JC (2010) Heyde’s syndrome: from controversy to mainstream. Thromb Haemost 103(2):251–253
Vincentelli A et al (2003) Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349(4):343–349
Ibrahim H, Rondina MT, Kleiman NS (2018) Von Willebrand factor and the aortic valve: concepts that are important in the transcatheter aortic valve replacement era. Thromb Res 170:20–27
Van Belle E et al (2016) Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement. N Engl J Med 375(4):335–344
Froom P et al (1988) Von Willebrand factor and mitral valve prolapse. Thromb Haemost 60(2):230–231
Blackshear JL et al (2011) Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc 86(3):219–224
Onimoe G et al (2011) Acquired von Willebrand Syndrome in congenital heart disease: does it promote an increased bleeding risk? Br J Haematol 155(5):622–624
Federici AB et al (2013) Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 39(2):191–201
Bongers TN et al (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672–2677
Pedrazzini G et al (2016) Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI. Blood 127(23):2934–2936
Jacquemin M, Peerlinck K (2015) Free hemoglobin: a boost to platelet thrombi. Blood 126(20):2262–2263
Muslem R, Caliskan K, Leebeek FWG (2018) Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost 16(3):429–440
Da Q et al (2014) Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 123(17):2715–2721
Selvam SN et al (2017) Abnormal angiogenesis in blood outgrowth endothelial cells derived from von Willebrand disease patients. Blood Coagul Fibrinolysis 28(7):521–533
Bartoli CR et al (2018) Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis. Circ Heart Fail 11(9):e004638
Starling RC et al (2014) Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370(1):33–40
Zhou Z et al (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101(6):1070–1077
Arkebauer MR et al (2011) Carbon monoxide and nitric oxide modulate alpha(2)-antiplasmin and plasmin activity: role of heme. Blood Coagul Fibrinolysis 22(8):712–719
Meyer AL et al (2014) Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2(2):141–145
Shankaran H, Neelamegham S (2004) Hydrodynamic forces applied on intercellular bonds, soluble molecules, and cell-surface receptors. Biophys J 86(1 Pt 1):576–588
Shim K et al (2008) Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 111(2):651–657
Letsou GV et al (2005) Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 24(1):105–109
Uriel N et al (2014) Device thrombosis in HeartMate II continuous-flow left ventricular assist devices: a multifactorial phenomenon. J Heart Lung Transplant 33(1):51–59
Vincent F et al (2018) Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support. J Am Coll Cardiol 71(19):2106–2118
Brehm MA et al (2014) von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. Thromb Haemost 112(1):96–108
Keesler DA, Flood VH (2018) Current issues in diagnosis and treatment of von Willebrand disease. Research and Practice in Thrombosis and Haemostasis 2(1):34–41
Draper K et al (2015) Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34(1):132–134
Borel-Derlon A et al (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 5(6):1115–1124
Grosman-Rimon L et al (2018) The Physiological Rationale for Incorporating Pulsatility in Continuous-Flow Left Ventricular Assist Devices. Cardiol Rev 26(6):294–301
Edwards AL et al (2018) Association of Pulsatility with Gastrointestinal Bleeding in a Cohort of HeartMate II Recipients. ASAIO J 64(4):472–479
Halder LC et al (2017) Time in Therapeutic Range for Left Ventricular Assist Device Patients Anticoagulated With Warfarin: a Correlation to Clinical Outcomes. ASAIO J 63(1):37–40
Molina TL et al (2018) Gastrointestinal Bleeding in Left Ventricular Assist Device: octreotide and Other Treatment Modalities. ASAIO J 64(4):433–439
Hollis IB et al (2017) Inhaled Desmopressin for Refractory Gastrointestinal Bleeding in a Patient With a HeartMate II Left Ventricular Assist Device. ASAIO J 63(4):e47–e49
Goudemand J et al (2005) Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 3(10):2219–2227
Tsai HM et al (1997) Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834 W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood 89(6):1954–1962
Rauch A et al (2014) Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thromb Haemost 112(5):1014–1023
Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 25(13):2019–2028
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mehta, R., Athar, M., Girgis, S. et al. Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians. J Thromb Thrombolysis 48, 14–26 (2019). https://doi.org/10.1007/s11239-019-01849-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-019-01849-2